<DOC>
	<DOCNO>NCT02961218</DOCNO>
	<brief_summary>To determine effect canakinumab versus placebo daily pain experience sickle cell anemia patient ( Reduction average daily pain VAS period Week 8 12 compare baseline level ) .</brief_summary>
	<brief_title>Study Efficacy , Safety Tolerability ACZ885 ( Canakinumab ) Pediatric Young Adult Patients With Sickle Cell Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female subject age 1220 year age ( inclusive ) diagnose sickle cell anemia ( HbSS ) sickle beta0 thalassemia ( document family study , analysis either hemoglobin DNA ) . Patient 's write informed consent ≥18 year age must obtain assessment perform . Parent legal guardian 's write informed consent child 's assent , appropriate , required assessment perform patient &lt; 18 year age . Detectable baseline background episodic pain measure daily ediary 1 2 week screen period define : Average daily pain score ≥ 1 cm without analgesic use period least 7 day and/or , At least one episode pain require analgesic use period 14 day . History ≥3 vasoocclusive pain episode past year , define pain , nonsickle cell identifiable cause require analgesia interferes activity daily live 2h . History known hypersensitivity canakinumab . Ongoing treatment past 2 year red blood cell transfusion therapy , evidence iron overload require chelation therapy . Transcranial Doppler ultrasound past year demonstrate velocity middle anterior cerebral internal carotid artery ≥200 cm/sec . Administration blood product within 3 week screen visit . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Sickle cell disease</keyword>
	<keyword>hemoglobinopathy</keyword>
	<keyword>pediatric</keyword>
</DOC>